Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Reports

• Most laboratories across Africa are not ready for AMR testing.
• Only 1.3% of the 50,000 medical laboratories forming the laboratory networks of the 14 participating Member States conduct bacteriology testing.
• Only a fraction can handle the scientific processes needed to evaluate AMR.
• In eight of the 14 countries, more than half of the population is out of reach of any bacteriology laboratory.
• Clinical and treatment data are not being linked to laboratory results, making it hard to understand what’s driving AMR.
• Out of ~187,000 samples tested for AMR, around 88% had no information on patients’ clinical profiles, including diagnosis/origin of infection, presence of indwelling device comorbidities or antimicrobial usage.
• Only four drugs comprised more than two-thirds (67%) of all the antibiotics used in healthcare settings.
• Stronger medicines to treat more resistant infections were not available, suggesting limited access to some groups of antibiotics.

Reports

The reports published here provide insight into the specific situation of each of the MAAP-participating Member States. Country data can inform national AMR containment plans and serve as baseline to prospectively monitor AMR, AMC and the strengthening of bacteriology laboratories.

Each Member State report is available below to download in PDF.